A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
NCT03507166 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43
Last updated 2019-08-21
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
Conditions
Interventions
- DRUG
-
RC48-ADC
2 mg/kg IV every 2 weeks
Sponsors & Collaborators
-
RemeGen Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-28
- Primary Completion
- 2018-10-29
- Completion
- 2018-10-29
Countries
- China
Study Locations
More Related Trials
-
PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
NCT05170568 ·Status: UNKNOWN ·Phase: PHASE1
-
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors
NCT04981691 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
NCT07093086 ·Status: WITHDRAWN ·Phase: PHASE1
-
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
NCT07010523 ·Status: RECRUITING ·Phase: NA
-
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
NCT04650724 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
NCT06586658 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
NCT01935843 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT04835519 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms
NCT05990621 ·Status: RECRUITING ·Phase: PHASE1
-
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
NCT05387226 ·Status: UNKNOWN ·Phase: PHASE1
-
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
NCT05594797 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
NCT06383507 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
NCT05509530 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies
NCT07338604 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
NCT05208853 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Universal CAR-γδT Cell Injection in the AML Patients
NCT05388305 ·Status: UNKNOWN ·Phase: NA
-
CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML
NCT02944162 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
NCT07109323 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
NCT07003568 ·Status: RECRUITING ·Phase: PHASE1
-
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
NCT07117175 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
NCT04537442 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
NCT06730256 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
NCT04814004 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
NCT04860817 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1